CBIO — Crescent Biopharma Income Statement
0.000.00%
Last trade - 00:00- $212.56m
- $206.94m
Annual income statement for Crescent Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 10.2 | 1.16 | 0.075 | 0.01 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 61.7 | 64.6 | 47.5 | 39.3 | 40 |
| Operating Profit | -51.5 | -63.4 | -47.4 | -39.3 | -40 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -51 | -63.4 | -46.7 | -36.9 | -37.9 |
| Net Income After Taxes | -51 | -63.4 | -46.7 | -36.9 | -37.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -51 | -63.4 | -46.7 | -36.9 | -37.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -51 | -63.4 | -46.7 | -36.9 | -37.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -112 | -123 | -88.9 | -58.3 | -49 |